Bio-Rad Laboratories Inc (NYSE: BIO) has reported earnings for its first fiscal quarter (ending March 31) of $13.46 versus $2.33 for the same period a year ago — an increase of 478%. This result exceeded the consensus estimate of $2.60 by $10.86. For the latest four quarters through March 31, E.P.S. were $-10.33 compared to $-6.31 a year ago.
Recent Price Action
Bio-Rad Laboratories Inc (NYSE: BIO) stock closed at $279.91 on 5/7/24 after a slight decline of -0.7%. NORMAL trading volume accompanied the decline. The stock has risen 1.0% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
BIO is expected to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Bio-Rad Laboratories has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Bio-Rad Laboratories has a good Appreciation Score of 80 but a very low Power Rating of 15, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment